Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China

Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China

In China, HIV-1-infected patients typically receive antiretroviral therapy (ART) that includes lamivudine (3TC) as a reverse-transcriptase inhibitor (RTI) (ART-3TC). Previous studies from certain developed countries have shown that, in ART-3TC, 3TC-resistant HBV progressively emerges at an annual ra...

Full description

Bibliographic Details
Main Authors: Gu, Lijun, Han, Yang, Li, Yijia, Zhu, Ting, Song, Xiaojing, Huang, Ying, Yang, Feifei, Guan, Shuo, Xie, Jing, Gohda, Jin, Hosoya, Noriaki, Kawana-Tachikawa, Ai, Liu, Wenjun, Gao, George Fu, Iwamoto, Aikichi, Li, Taisheng, Ishida, Takaomi
Format: Online
Language:English
Published: Public Library of Science 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4543549/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4543549/

Similar Items